A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein

Journal of Virology

Volumn 90, Issue 23, 2016, Pages 10774-10788

  Guo, Fang ^a   Wu, Shuo ^a   Julander, Justin ^b   Ma, Julia ^a   Zhang, Xuexiang ^a   Kulp, John ^a   Cuconati, Andrea ^a   Block, Timothy M ^a   Du, Yanming ^a   Guo, Ju Tao ^a   Chang, Jinhong ^a  

^a BARUCH S BLUMBERG INSTITUTE   (United States)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALANINE; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; ESTAZOLAM; GLYCINE; LORAZEPAM; MEMBRANE PROTEIN; NONSTRUCTURAL PROTEIN 4B; NORDAZEPAM; PRAZEPAM; PROLINE; RIBAVIRIN; SERINE; TEMAZEPAM; THREONINE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; BIOINFORMATICS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEATH; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; ENDOPLASMIC RETICULUM; FEMALE; GENETIC ANALYSIS; HAMSTER; HUMAN; HUMAN CELL; LIVER INJURY; MAMMAL CELL; MAXIMUM TOLERATED DOSE; MICROBIAL ACTIVITY; MOUSE; MUTATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRAL GENETICS; VIRION; VIRUS CULTURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 85001086085     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01253-16     Document Type: Article

References (72)

1. Monath TP, Vasconcelos PF. 2015. Yellow fever. J Clin Virol 64:160-173. http://dx.doi.org/10.1016/j.jcv.2014.08.030.
2. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59:895-900.
3. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J. 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56:159-167. http://dx.doi.org/10.1002/(SICI)1096-9071(199810)56:2 <159::AID-JMV10>3.0.CO;2-B.
4. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, Informal WHO Working Group on Geographic Risk for Yellow Fever. 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11:622-632. http://dx.doi.org/10.1016/S1473-3099(11)70147-5.
5. Maciel M, Jr, Cruz Fda S, Cordeiro MT, da Motta MA, Cassemiro KM, Maia Rde C, de Figueiredo RC, Galler R, Freire Mda S, August JT, Marques ET, Dhalia R. 2015. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis 9:e0003693. http://dx.doi.org/10.1371/journal.pntd.0003693.
6. Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, Canderan G, Lawson B, Kopycinski J, Graham AS, Rowe DK, Smith MJ, Isern S, Michael S, Silvestri G, Vanderford TH, Castro E, Pantaleo G, Singer J, Gillmour J, Kiwanuka N, Nanvubya A, Schmidt C, Birungi J, Cox J, Haddad EK, Kaleebu P, Fast P, Sekaly RP, Trautmann L, Gaucher D. 2014. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 124:3147-3158. http: //dx.doi.org/10.1172/JCI75429.
7. Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, Miller JD, Pulendran B, Antia R, Ahmed R. 2015. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A 112:3050-3055. http: //dx.doi.org/10.1073/pnas.1500475112.
8. Julander JG. 2013. Experimental therapies for yellow fever. Antiviral Res 97:169-179. http://dx.doi.org/10.1016/j.antiviral.2012.12.002.
9. Beasley DW, McAuley AJ, Bente DA. 2015. Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy. Antiviral Res 115:48-70. http://dx.doi.org/10.1016/j.antiviral.2014.12.010.
10. Harris E, Holden KL, Edgil D, Polacek C, Clyde K. 2006. Molecular biology of flaviviruses. Novartis Found Symp 277:23-39. http://dx.doi.org /10.1002/0470058005.ch3.
11. Selisko B, Wang C, Harris E, Canard B. 2014. Regulation of flavivirus RNA synthesis and replication. Curr Opin Virol 9:74-83. http://dx.doi.org/10.1016/j.coviro.2014.09.011.
12. Diamond MS, Pierson TC. 2015. Molecular insight into dengue virus pathogenesis and its implications for disease control. Cell 162:488-492. http://dx.doi.org/10.1016/j.cell.2015.07.005.
13. Laurent-Rolle M, Morrison J, Rajsbaum R, Macleod JM, Pisanelli G, Pham A, Ayllon J, Miorin L, Martinez-Romero C, ten Oever BR, Garcia-Sastre A. 2014. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 16:314-327. http://dx.doi.org/10.1016/j.chom.2014.07.015.
14. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 79:8004-8013 http://dx.doi.org/10.1128/JVI.79.13.8004-8013.2005.
15. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. 2013. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100:500-519. http: //dx.doi.org/10.1016/j.antiviral.2013.09.013.
16. Behnam MA, Nitsche C, Boldescu V, Klein CD. 2016. The medicinal chemistry of dengue virus. J Med Chem 59:5622-5649. http://dx.doi.org /10.1021/acs.jmedchem.5b01653.
17. Chang J, Block TM, Guo JT. 2013. Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res 99: 251-260. http://dx.doi.org/10.1016/j.antiviral.2013.06.011.
18. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res 85:450-462. http://dx.doi.org/10.1016/j.antiviral.2009.12.011.
19. Noble CG, Shi PY. 2012. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res 96:115-126. http: //dx.doi.org/10.1016/j.antiviral.2012.09.007.
20. Scaturro P, Trist IM, Paul D, Kumar A, Acosta EG, Byrd CM, Jordan R, Brancale A, Bartenschlager R. 2014. Characterization of the mode of action of a potent dengue virus capsid inhibitor. J Virol 88:11540-11555. http://dx.doi.org/10.1128/JVI.01745-14.
21. Wu H, Bock S, Snitko M, Berger T, Weidner T, Holloway S, Kanitz M, Diederich WE, Steuber H, Walter C, Hofmann D, Weissbrich B, Spannaus R, Acosta EG, Bartenschlager R, Engels B, Schirmeister T, Bodem J. 2015. Novel dengue virus NS2B/NS3 protease inhibitors. Antimicrob Agents Chemother 59:1100-1109. http://dx.doi.org/10.1128/AAC.03543-14.
22. Timiri AK, Sinha BN, Jayaprakash V. 2016. Progress and prospects on DENV protease inhibitors. Eur J Med Chem 117:125-143. http://dx.doi.org/10.1016/j.ejmech.2016.04.008.
23. Behnam MA, Graf D, Bartenschlager R, Zlotos DP, Klein CD. 2015. Discovery of nanomolar dengue and West Nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue. J Med Chem 58:9354-9370 http://dx.doi.org/10.1021/acs.jmedchem.5b01441.
24. Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB, Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page J, Stavale E, Stone MA, Fuller KP, Lovejoy C, Leeds JM, Hruby DE, Jordan R. 2013. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother 57:1902-1912 http://dx.doi.org/10.1128/AAC.02251-12.
25. Xie X, Zou J, Wang QY, Shi PY. 2015. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res 118:39-45. http://dx.doi.org/10.1016/j.antiviral.2015.03.007.
26. Zou B, Chan WL, Ding M, Leong SY, Nilar S, Seah PG, Liu W, Karuna R, Blasco F, Yip A, Chao A, Susila A, Dong H, Wang QY, Xu HY, Chan K, Wan KF, Gu F, Diagana TT, Wagner T, Dix I, Shi PY, Smith PW. 2015 Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitors. ACS Med Chem Lett 6:344-348. http://dx.doi.org/10.1021/ml500521r.
27. Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, Zou G, Monaghan P, Chung KY, Dong H, Liu B, Bodenreider C, Lee G, Ding M, Chan WL, Wang G, Jian YL, Chao AT, Lescar J, Yin Z, Vedananda TR, Keller TH, Shi PY. 2011. Small molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem 286:6233-6240. http://dx.doi.org/10.1074 /jbc.M110.179184.
28. Lim SP, Noble CG, Shi PY. 2015. The dengue virus NS5 protein as a target for drug discovery. Antiviral Res 119:57-67. http://dx.doi.org/10.1016/j.antiviral.2015.04.010.
29. Chen YL, Yokokawa F, Shi PY. 2015. The search for nucleoside/ nucleotide analog inhibitors of dengue virus. Antiviral Res 122:12-19. http://dx.doi.org/10.1016/j.antiviral.2015.07.010.
30. Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB, Schneider C, Wineinger KA, Page JM, Harver C, Stavale E, Tyavanagimatt S, Stone MA, Bartenschlager R, Scaturro P, Hruby DE, Jordan R. 2013 A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother 57:15-25. http://dx.doi.org/10.1128/AAC.01429-12.
31. Zou J, Xie X, Wang QY, Dong H, Lee MY, Kang C, Yuan Z, Shi PY. 2015 Characterization of dengue virus NS4A and NS4B protein interaction. J Virol 89:3455-3470. http://dx.doi.org/10.1128/JVI.03453-14.
32. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A 106:20435-20439. http://dx.doi.org/10.1073/pnas.0907010106.
33. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP. 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 207:1442-1450. http://dx.doi.org/10.1093/infdis/jis470.
34. Chen YL, Abdul Ghafar N, Karuna R, Fu Y, Lim SP, Schul W, Gu F, Herve M, Yokohama F, Wang G, Cerny D, Fink K, Blasco F, Shi PY. 2014 Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol 88:1740-1747. http://dx.doi.org/10.1128/JVI.02841-13.
35. Julander JG, Bantia S, Taubenheim BR, Minning DM, Kotian P, Morrey JD, Smee DF, Sheridan WP, Babu YS. 2014. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob Agents Chemother 58:6607-6614. http://dx.doi.org/10.1128 /AAC.03368-14.
36. Julander JG, Furuta Y, Shafer K, Sidwell RW. 2007. Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob Agents Chemother 51:1962-1966. http://dx.doi.org/10.1128/AAC.01494-06.
37. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53:202-209. http://dx.doi.org/10.1128/AAC.01074-08.
38. Julander JG, Jha AK, Choi JA, Jung KH, Smee DF, Morrey JD, Chu CK. 2010 Efficacy of 2=-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Res 86:261-267. http://dx.doi.org/10.1016/j.antiviral.2010.03.004.
39. Julander JG, Morrey JD, Blatt LM, Shafer K, Sidwell RW. 2007. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res 73:140-146. http://dx.doi.org/10.1016/j.antiviral.2006.08.008.
40. Patkar CG, Larsen M, Owston M, Smith JL, Kuhn RJ. 2009. Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob Agents Chemother 53:4103-4114. http://dx.doi.org/10.1128/AAC.00074-09.
41. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
42. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229:726-733. http://dx.doi.org/10.1126/science.4023707.
43. Bredenbeek PJ, Kooi EA, Lindenbach B, Huijkman N, Rice CM, Spaan WJ. 2003. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol 84:1261-1268 http://dx.doi.org/10.1099/vir.0.18860-0.
44. Qu X, Pan X, Weidner J, Yu W, Alonzi D, Xu X, Butters T, Block T, Guo JT, Chang J. 2011. Inhibitors of endoplasmic reticulum α-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother 55:1036-1044. http://dx.doi.org/10.1128 /AAC.01319-10.
45. Guo F, Zhao X, Gill T, Zhou Y, Campagna M, Wang L, Liu F, Zhang P, DiPaolo L, Du Y, Xu X, Jiang D, Wei L, Cuconati A, Block TM, Guo JT, Chang J. 2014. An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. Antiviral Res 107:56-65. http://dx.doi.org/10.1016/j.antiviral.2014.04.010.
46. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi PY, Block TM, Guo JT. 2010. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J Virol 84:8332-8341. http://dx.doi.org/10.1128/JVI.02199-09.
47. Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA, Du Y, Alonzi DS, Yu W, Ye H, Liu F, Guo JT, Mehta A, Cuconati A, Butters TD, Bavari S, Xu X, Block TM. 2013. Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res 98:432-440. http://dx.doi.org/10.1016/j.antiviral.2013.03.023.
48. Le Fur G, Vaucher N, Perrier ML, Flamier A, Benavides J, Renault C, Dubroeucq MC, Gueremy C, Uzan A. 1983. Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci 33:449-457. http://dx.doi.org/10.1016/0024-3205(83)90794-4.
49. Speth RC, Wastek GJ, Yamamura HI. 1979. Benzodiazepine receptors: temperature dependence of [3H]flunitrazepam binding. Life Sci 24:351-357 http://dx.doi.org/10.1016/0024-3205(79)90331-X.
50. Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C. 2009. Translocator protein ligands as promising therapeutic tools for anxiety disorders. Curr Med Chem 16:3359-3380. http://dx.doi.org/10.2174 /092986709789057653.
51. Sieghart W, Ramerstorfer J, Sarto-Jackson I, Varagic Z, Ernst M. 2012. A novel GABA(A) receptor pharmacology: drugs interacting with the alpha( +) beta(-) interface. Br J Pharmacol 166:476-485. http://dx.doi.org /10.1111/j.1476-5381.2011.01779.x.
52. Zisterer DM, Williams DC. 1997. Peripheral-type benzodiazepine receptors. Gen Pharmacol 29:305-314. http://dx.doi.org/10.1016 /S0306-3623(96)00473-9.
53. Miller S, Sparacio S, Bartenschlager R. 2006. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J Biol Chem 281:8854-8863. http://dx.doi.org/10.1074/jbc.M512697200.
54. Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CK, Walther P, Fuller SD, Antony C, Krijnse-Locker J, Bartenschlager R. 2009. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5:365-375. http://dx.doi.org/10.1016/j.chom.2009.03.007.
55. Green AM, Beatty PR, Hadjilaou A, Harris E. 2014. Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol 426:1148-1160. http://dx.doi.org/10.1016/j.jmb.2013.11.023.
56. Henderson EA, Alber DG, Baxter RC, Bithell SK, Budworth J, Carter MC, Chubb A, Cockerill GS, Dowdell VC, Fraser IJ, Harris RA, Keegan SJ, Kelsey RD, Lumley JA, Stables JN, Weerasekera N, Wilson LJ, Powell KL. 2007. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 50:1685-1692.
57. Zhang P, Zhang N, Korba BE, Hosmane RS. 2005. Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. Bioorg Med Chem Lett 15:5397-5401. http://dx.doi.org/10.1016 /j.bmcl.2005.09.015.
58. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL. 2011. Identification of a smallmolecule entry inhibitor for filoviruses. J Virol 85:3106-3119. http://dx.doi.org/10.1128/JVI.01456-10.
59. Schimer J, Cigler P, Vesely J, Grantz Saskova K, Lepsik M, Brynda J, Rezacova P, Kozisek M, Cisarova I, Oberwinkler H, Kraeusslich HG, Konvalinka J. 2012. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold. J Med Chem 55:10130-10135 http://dx.doi.org/10.1021/jm301249q.
60. Zmurko J, Neyts J, Dallmeier K. 2015. Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. Rev Med Virol 25:205-223. http://dx.doi.org/10.1002/rmv.1835.
61. Zou J, Xie X, Lee le T, Chandrasekaran R, Reynaud A, Yap L, Wang QY, Dong H, Kang C, Yuan Z, Lescar J, Shi PY. 2014. Dimerization of flavivirus NS4B protein. J Virol 88:3379-3391. http://dx.doi.org/10.1128 /JVI.02782-13.
62. Bartenschlager R, Miller S. 2008. Molecular aspects of dengue virus replication. Future Microbiol 3:155-165. http://dx.doi.org/10.2217 /17460913.3.2.155.
63. Wang QY, Dong H, Zou B, Karuna R, Wan KF, Zou J, Susila A, Yip A, Shan C, Yeo KL, Xu H, Ding M, Chan WL, Gu F, Seah PG, Liu W, Lakshminarayana SB, Kang C, Lescar J, Blasco F, Smith PW, Shi PY. 2015 Discovery of dengue virus NS4B inhibitors. J Virol 89:8233-8244. http://dx.doi.org/10.1128/JVI.00855-15.
64. de Wispelaere M, LaCroix AJ, Yang PL. 2013. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol 87:7367-7381. http://dx.doi.org/10.1128/JVI.00632-13.
65. van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP. 2013. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res 99:165-171. http://dx.doi.org/10.1016/j.antiviral.2013.05.011.
66. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY. 2011. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 85: 11183-11195. http://dx.doi.org/10.1128/JVI.05468-11.
67. van Cleef KW, Overheul GJ, Thomassen MC, Marjakangas JM, van Rij RP. 2016. Escape mutations in NS4B render dengue virus insensitive to the antiviral activity of the paracetamol metabolite AM404. Antimicrob Agents Chemother 60:2554-2557. http://dx.doi.org/10.1128/AAC.02462-15.
68. Cannalire R, Barreca ML, Manfroni G, Cecchetti V. 2016. A journey around the medicinal chemistry of hepatitis C virus inhibitors targeting NS4B: from target to preclinical drug candidates. J Med Chem 59:16-41. http://dx.doi.org/10.1021/acs.jmedchem.5b00825.
69. Chang J, Block TM, Guo JT. 2015. Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections. Antivir Ther 20:257-259. http://dx.doi.org/10.3851/IMP2907.
70. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org/10.1038/nature08960.
71. Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT. 2013. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 87:6931-6942. http://dx.doi.org/10.1128 /JVI.00582-13.
72. Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. 2015. Core protein: a pleiotropic keystone in the HBV life cycle. Antiviral Res 121:82-93. http://dx.doi.org/10.1016/j.antiviral.2015.06.020.